Large-Scale Screening For Childhood Cancer

December 21, 1996

Infant screening for neuroblastoma--one of the most common forms of solid tumors in young children--fails to detect the most severe form of the disease, according to a group of international researchers led by University of Minnesota faculty. After screening nearly 500,000 Canadian infants for neuroblastoma, the group found that screening failed to detect the most severe neuroblastomas even though it detected twice as many cancers as had been expected. The researchers conclude that, if left to run their course, some neuroblastomas detected by screening in infancy either go away or fail to progress. Results of the study appear in the December 21 issue of The Lancet.

"Widespread infant screening for neuroblastoma does not save lives and could subject infants to unnecessary cancer treatments," said Mendel Tuchman, one of three principal investigators in the study, who is also a professor of pediatrics and member of the University of Minnesota Cancer Center. He added that no such routine screening programs are currently in place in the United States. Other principal investigators were William Woods, professor of pediatrics and director of the South Carolina Cancer Center at the University of South Carolina, and Bernard Lemieux, professor of pediatrics at the University of Sherbrooke in Quebec. Leslie Robison, holder of the Cancer Center Children's Cancer Research Fund chair in pediatric cancer at the University of Minnesota, and Russell Luepker, professor and head of the division of epidemiology in the University of Minnesota School of Public Health, also were involved in the study.

"When the disease develops before the child is a year old, it is often successfully treated," said Tuchman, whose laboratory developed and performed the screening test. "After that age, it could evolve rapidly into an advanced stage disease with a very high mortality. It is extremely unfortunate that infant screening does not detect the severe neuroblastomas that develop in older infants."

Researchers now believe that there are at least two distinct types of neuroblastoma. Those that appear at birth or shortly thereafter may resolve spontaneously without leaving any trace of the disease. A more advanced form appears in older infants and carries a high mortality. One in 7,000 children is diagnosed with neuroblastoma, making it one of the most common malignant tumors in young children. In 90 percent of cases, the disease affects those under five years of age.

The researchers screened children born between 1989 and 1994 in the province of Quebec for neuroblastoma. Quebec was chosen for the study because it had an established program to screen for metabolic defects at the age of three weeks. Parents submitted urine samples from their children at the ages of three weeks and six months. Researchers analyzed samples from 425,816 3-week-olds (91 percent of those eligible). Of those, samples from 349,706 (75 percent) were again analyzed at 6 months of age. The 118 detected neuroblastoma cases were more than twice the 54 expected when compared to newborns in Ontario and Minnesota, where screening was not performed.

"While screening for cancer has great appeal, these results demonstrate the importance of large-scale studies to make sure we don't do more harm than good and end up wasting millions of dollars," said Robison. Prior to the study, many people had advocated for widespread infant screening in the United States, based on preliminary reports from programs in Japan.

The $6.6 million Quebec Neuroblastoma Screening Project was funded by the National Cancer Institute. The NCI grant was based on the results of a pilot study in the Twin Cities funded by the American Cancer Society. The University of Minnesota, a leader in cancer research since 1911, formed the Cancer Center in 1991 to coordinate cancer-related programs. The university receives more than $20 million a year in research grants from the National Cancer Institute and other federal sources.

University of Minnesota

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to